IL18 and adult-onset Still disease: Growing evidence indicates that the NLRP3 inflammasome plays a pivotal pathogenic role in autoinflammatory diseases: pharmacological inhibition of NLRP3 activation results in potent therapeutic effects, as observed through good response to interleukin (IL)-1β inhibitors and IL-18 binding protein in AOSD patients [25].